Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

PT-141 Bremelanotide 10mg

PT-141 Bremelanotide 10mg Research Handling Note: For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolution. *Rec

By Recovery & Performance Peptides Editorial Team

PT-141 Bremelanotide 10mg

Research Handling Note:

For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolution. *Reconstitution solutions are supplied separately.

Stock: 2080

Model: PT-141 Bremelanotide

Molecular Formula: C52H72N14O12

SKU: PT1-022

Research Only: Yes

Certificate of analysis

Description

Technical Data

PT-141 (Bremelanotide) 10mg – High-Purity Research Peptide

PT-141 (Bremelanotide) 10mg is a high-purity research peptide designed for advanced scientific studies in biochemistry and related fields. This lyophilised peptide is manufactured to strict quality standards, ensuring precision and reliability in laboratory settings.

Product Information

Product Name: PT-141 (Bremelanotide) 10mg

Catalogue Number: UK-PT141

CAS Number: 189691-06-3

Molecular Formula: C₅₀H₆₈N₁₄O₁₀

Molecular Weight: 1025.2 g/mol

Purity: ≥98% (HPLC Verified)

Peptide Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Form: Lyophilised Solid

Usage and Storage

PT-141 (Bremelanotide) is supplied as a lyophilised solid to maintain maximum stability and ease of handling in research environments. For best results, refer to our reconstitution and storage guidelines.

Synthesis and Quality Control

Purity and Consistency: Each batch undergoes rigorous quality control to ensure a purity level of ≥98%, providing reliable and reproducible results.

Manufacturing Standards: Synthesised using advanced techniques to meet high scientific research standards.

Legal and Compliance Information

For Research Use Only: PT-141 (Bremelanotide) is strictly intended for scientific and laboratory research.

Not for Human Consumption: This product is not approved for clinical or therapeutic use.

Regulatory Compliance: Manufactured under strict quality and safety protocols to support scientific research.

Why Choose This PT-141?

High purity (≥98%) for precise research applications

Laboratory-grade synthesis for consistent scientific studies

Stringent quality control to ensure research reliability

Order PT-141 (Bremelanotide) 10mg today to enhance your research with a premium-quality peptide.

Identification

Molecular Weight (g/mol)

1025.16 g/mol

Peptide Sequence

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

CAS Number

189691-06-3

Physical and Chemical Properties

Molecular Formula

C50H68N14O10

Appearance

White to off-white lyophilised powder

Melting Point

Not applicable (decomposes before melting)

Research Use and Safety

Caution

Handle using appropriate PPE and in compliance with relevant laboratory safety standards.

Intended Use

For laboratory research use only. Not for human or veterinary use.

Hazard Classification

Not classified as hazardous under GHS for research quantities

Storage, Handling and Stability

Storage Temperature, Opened

-20 °C, minimise freeze-thaw cycles

Storage Temperature, Unopened

-20 °C recommended for long-term storage

Shelf Life

2 years unopened under recommended conditions

Reconstitution Stability

Stable for up to 28 days at 2-8 °C in aqueous solution under sterile conditions

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Safely Source Peptides: Avoiding Scams and Poor Quality

Learn how to safely source research peptides by verifying Certificates of Analysis, recognizing red flags, understanding purity metrics, and ensuring proper storage. A complete guide to avoiding scams and low-quality suppliers.
DOSAGE SOURCE

Dosage Protocols

FDA-Approved Dosing (Vyleesi): 1.75 mg subcutaneously, administered at least 45 minutes before anticipated sexual activity Maximum one dose per 24-hour period Maximum 8 doses per month Patients should determine their optimal timing based on personal experience with onset and duration of effects Off-Label Dosing Considerations: Off-label use in men typically follows the same 1.75 mg subcutaneous dose, though some clinicians adjust within a range of 1 to 2 mg based on individual response and tolerability. Lower starting doses (0.5 to 1 mg) may be considered for first-time users to assess tolerance, particularly regarding nausea. Anti-nausea medication such as ondansetron taken 30 minutes before PT-141 can reduce gastrointestinal side effects. The monthly frequency limit of 8 doses is based on the prescribing information and reflects the on-demand nature of the drug. PT-141 is not intended for daily use, and dose frequency should be kept to the minimum effective amount.
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

PT-141 for Men: Off-Label Use and Clinical Evidence

It is important to state clearly that PT-141 is not FDA-approved for use in men. Its use in male sexual dysfunction is considered off-label. That said, clinicians have explored PT-141 in men for years, particularly in cases involving: Erectile dysfunction (ED) Psychogenic ED Poor response to PDE5 inhibitors

RESEARCH

Early Phase Research

Phase I and II studies by Molinoff et al. and Diamond et al. established the proof of concept for melanocortin agonists in sexual dysfunction, demonstrating dose-dependent effects on subjective arousal and physiological measures in both men and women. These early studies confirmed the central mechanism of action and informed the dose selection for the pivotal Phase III program.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Key Comparisons: PT-141 vs MT-II vs Alpha-MSH in Sexual Arousal Research

MT-II (Melanotan-II, cyclic [Nle⁴, D-Phe⁷]-alpha-MSH): Non-selective melanocortin agonist; MC1R (tanning, Ki ~0.2nM), MC3R (Ki ~0.3nM), MC4R (Ki ~0.4nM), MC5R (Ki ~0.6nM). Strong …

Continue reading

Related articles